| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| A Pilot Study of Value of Information Analysis to Support Research Recommendations for the National Institute for Health and Clinical Excellence |
0 |
0 |
1 |
109 |
0 |
1 |
4 |
604 |
| Accounting for timing when assessing health-related policies |
0 |
0 |
0 |
11 |
0 |
0 |
2 |
38 |
| An Economic Approach to Clinical Trial Design and Research Priority Setting |
0 |
0 |
0 |
0 |
1 |
1 |
3 |
879 |
| Appropriate Perspectives for Health Care Decisions |
1 |
2 |
4 |
673 |
2 |
5 |
13 |
2,035 |
| Assessing health opportunity costs for the Indian health care systems |
0 |
1 |
2 |
31 |
3 |
7 |
24 |
161 |
| Assessing the impact of health care expenditures on mortality using cross-country data |
0 |
0 |
1 |
84 |
0 |
2 |
5 |
109 |
| Bayesian Value-of-Information Analysis: An Application to a Policy Model of Alzheimer's Disease |
0 |
0 |
0 |
600 |
1 |
1 |
4 |
2,319 |
| Budget allocation and the revealed social rate of time preference for health |
0 |
0 |
0 |
85 |
0 |
0 |
4 |
356 |
| Budgetary policies and available actions: a generalisation of decision rules for allocation and research decisions |
0 |
0 |
0 |
45 |
0 |
0 |
3 |
180 |
| Cost per DALY averted thresholds for low- and middle-income countries: evidence from cross country data |
0 |
1 |
7 |
101 |
4 |
7 |
27 |
300 |
| Country-level cost-effectiveness thresholds: initial estimates and the need for further research |
0 |
0 |
0 |
31 |
0 |
2 |
5 |
146 |
| Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions |
0 |
0 |
0 |
28 |
0 |
0 |
8 |
152 |
| Defining and characterising structural uncertainty in decision analytic models |
0 |
0 |
0 |
187 |
1 |
3 |
11 |
895 |
| Dimensions of design space: a decision-theoretic approach to optimal research design |
0 |
0 |
0 |
53 |
0 |
1 |
4 |
456 |
| Effects of Fundholding on the Prescribing and Referral Behavior of General Practitioners |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
119 |
| Estimating the marginal productivity of the English National Health Service from 2003/04 to 2012/13 |
0 |
0 |
3 |
56 |
0 |
2 |
14 |
125 |
| Expected health benefits of additional evidence: Principles, methods and applications |
0 |
0 |
0 |
22 |
0 |
1 |
5 |
101 |
| Improving the efficiency and relevance of health technology assessent: the role of iterative decision analytic modelling |
0 |
0 |
0 |
89 |
0 |
0 |
2 |
368 |
| Is an ounce of prevention worth a pound of cure? Estimates of the impact of English public health grant on mortality and morbidity |
0 |
0 |
1 |
66 |
0 |
0 |
24 |
318 |
| Mark versus Luke? Appropriate Methods for the Evaluation of Public Health Interventions |
1 |
3 |
3 |
370 |
2 |
5 |
10 |
1,065 |
| Methods for the estimation of the NICE cost effectiveness threshold |
0 |
4 |
12 |
188 |
2 |
8 |
27 |
761 |
| Modelling the behaviour of general practitioners: a theoretical foundation for studies of fundholding |
0 |
0 |
0 |
31 |
0 |
0 |
2 |
147 |
| Setting research priorities in Global Health:Appraising the value of evidence generation activities to support decision-making in health care |
0 |
0 |
2 |
22 |
0 |
0 |
4 |
43 |
| Supporting the development of an essential health package: principles and initial assessment for Malawi |
0 |
0 |
2 |
67 |
2 |
6 |
16 |
305 |
| The NICE Cost-Effectiveness Threshold: What it is and What that Means |
0 |
1 |
2 |
85 |
0 |
1 |
7 |
282 |
| The Role of Decision Analysis in Structuring the Economic Evaluation of Sequential Clinical Decision Problems |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
211 |
| The value of implementation and the value of information: combined and uneven development |
0 |
0 |
0 |
34 |
1 |
2 |
7 |
180 |
| Uncertainty, evidence and irrecoverable costs: Informing approval, pricing and research decisions for health technologies |
0 |
0 |
0 |
31 |
0 |
0 |
4 |
198 |
| Using cost-effectiveness thresholds to determine value for money in low- and middle-income country healthcare systems: Are current international norms fit for purpose? |
1 |
1 |
3 |
160 |
1 |
2 |
12 |
490 |
| Value-based pricing for pharmaceuticals: Its role, specification and prospects in a newly devolved NHS |
1 |
3 |
6 |
707 |
1 |
4 |
12 |
2,217 |
| Total Working Papers |
4 |
16 |
49 |
3,966 |
21 |
61 |
265 |
15,560 |
LogEc is hosted by the
Örebro University School of Business.